Last Updated: April 30, 2026

CLINICAL TRIALS PROFILE FOR MEKINIST


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Mekinist

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01438554 ↗ Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed GlaxoSmithKline Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 ↗ Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed National Comprehensive Cancer Network Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 ↗ Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed Novartis Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 ↗ Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed Sidney Kimmel Comprehensive Cancer Center Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 ↗ Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mekinist

Condition Name

Condition Name for Mekinist
Intervention Trials
Melanoma 14
Advanced Malignant Solid Neoplasm 8
Recurrent Melanoma 7
Refractory Malignant Solid Neoplasm 7
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mekinist
Intervention Trials
Melanoma 27
Neoplasms 16
Carcinoma 16
Carcinoma, Non-Small-Cell Lung 11
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mekinist

Trials by Country

Trials by Country for Mekinist
Location Trials
United States 533
Canada 18
United Kingdom 12
Australia 11
France 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mekinist
Location Trials
Texas 30
California 25
Massachusetts 22
Pennsylvania 21
Ohio 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mekinist

Clinical Trial Phase

Clinical Trial Phase for Mekinist
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 59
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mekinist
Clinical Trial Phase Trials
Recruiting 35
Active, not recruiting 30
Completed 11
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mekinist

Sponsor Name

Sponsor Name for Mekinist
Sponsor Trials
National Cancer Institute (NCI) 42
Novartis 15
Novartis Pharmaceuticals 12
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mekinist
Sponsor Trials
Other 103
Industry 68
NIH 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Mekinist (trametinib): Clinical Trials Update, Market Analysis, and Projection

Last updated: April 27, 2026

Mekinist is the brand name of trametinib, a MEK inhibitor marketed by Novartis (U.S. and some geographies) and distributed under related arrangements globally. Trametinib’s commercial trajectory is tied to (1) melanoma expansion and combination usage and (2) durability of kinase inhibitor competition in MAPK-driven oncology. The clinical pipeline and near-term market outlook are dominated by label-sustaining studies (new combinations, new lines, and real-world evidence) rather than a single transformative registration readout.

What is Mekinist’s current clinical position by disease and trial intent?

On-label melanoma and combination strategy

Trametinib is established in advanced melanoma with a focus on blocking MEK signaling and improving outcomes when paired with BRAF inhibition in BRAF-mutant disease. The clinical update for the drug class has trended toward combination optimization and sequencing rather than monotherapy expansion.

Key patterns seen across MEK inhibitor development programs include:

  • Combination expansion to deepen response rates versus targeted therapy alone
  • Sequencing trials to determine best timing against BRAF inhibition or immunotherapy
  • Biomarker stratification using BRAF status and downstream pathway signatures

Emerging indications and trial readouts

For MEK inhibitors, most active late-stage activity typically targets:

  • Other solid tumors with pathway activation (MAPK-driven cancers)
  • Combination regimens with immuno-oncology agents, EGFR-pathway therapies, or other targeted agents
  • Resistance biology via next-generation combinations and adaptive trial designs

Net clinical implication for Mekinist: growth is most likely to come from incremental label broadening and combination adoption, while maintaining share where current regimens remain standard of care.

Which clinical endpoints and trial designs matter for Mekinist decision-making?

When investors and R&D teams evaluate trametinib programs, decision quality usually hinges on these measurable levers:

  • PFS and OS: progression-free survival and overall survival in phase 3 or confirmatory phase 2/3 settings
  • ORR and DOR: objective response rate and duration of response in phase 2 expansion
  • Safety profile in combination: rash, cardiomyopathy, ocular toxicity, and treatment discontinuation rates
  • Biomarker enrichment: BRAF V600 status (for melanoma) and pathway activation markers in broader solid tumors
  • Management of resistance: trial cohorts that address acquired resistance patterns and treatment sequencing

These are the metrics that change payer positioning and guideline inclusion.

What is the market landscape for Mekinist (trametinib)?

Therapeutic category

Mekinist is a targeted oncology drug in the MAPK pathway class (MEK inhibitor). Its market is driven by:

  • BRAF V600 mutation prevalence in melanoma
  • Adoption of targeted combinations where rapid disease control is prioritized
  • Competition from other MEK/ERK-axis inhibitors and upstream BRAF-targeted agents
  • Ongoing immuno-oncology integration into first-line care pathways

Competitive set (practical)

Trametinib competes in treatment regimens where MEK inhibition is a component, typically against:

  • Other MEK inhibitors used in melanoma combination strategies
  • Alternative targeted combinations anchored on BRAF inhibition
  • Immunotherapy-led first-line pathways where MEK inhibitors shift to later lines depending on patient profile and guideline position

Commercial drivers

The dominant commercial drivers for Mekinist are:

  1. Guideline inclusion in advanced melanoma regimens for BRAF V600-mutant disease
  2. Combination uptake with BRAF inhibitors where durable control is achieved
  3. Reimbursement and formulary placement in major markets
  4. Persistence and discontinuation patterns in real-world practice

Market projection: how should Mekinist be forecast over the next 3–5 years?

Projection framework (what to model)

A practical forecast for a MEK inhibitor like trametinib should model:

  • Addressable population: advanced melanoma incidence and BRAF V600 mutation proportion
  • Line-of-therapy share: proportion of patients receiving MEK inhibition in first-line versus later lines
  • Combination share: trametinib use frequency in BRAF inhibitor combinations versus other regimens
  • Net price and discounting: especially as competition intensifies or payer pressure increases
  • Time on treatment (ToT) and discontinuation: safety management and tolerability affects utilization
  • Loss risks: patent expiry dynamics for jurisdictions, plus any label erosion if new standards emerge

Base-case outlook

Trametinib market growth is most likely to be modest rather than explosive because:

  • Most high-value disease access is already established for melanoma
  • Incremental expansion depends on trial readouts and guideline updates
  • Competitor regimens increasingly define payer preference through demonstrated outcomes and tolerability

Upside and downside levers

  • Upside: new combination adoption or expanded label in additional solid tumors; favorable PFS/OS in confirmatory trials that change guideline inclusion
  • Downside: faster-than-expected shift to immunotherapy-first strategies for broader patient segments; increased payer switching to alternative targeted options

Clinical trials update: what to watch next for Mekinist (trametinib) R&D?

For business planning, the “watch list” for trametinib typically includes:

  • Confirmatory registrational studies with endpoints that support label expansion
  • Phase 2 expansion cohorts that de-risk phase 3 and support multi-indication strategy
  • Combination programs where the safety profile remains manageable across broader dosing schedules
  • Real-world evidence studies that quantify persistence, dose intensity, and discontinuation reasons

Business implication: Mekinist’s near-term value creation is most likely tied to label sustaining plus incremental expansion, with trial readouts that influence guideline and payer behavior.

Key regulatory and product considerations that affect market use

Safety and dosing

Clinical adoption of MEK inhibitors depends on managing class-specific adverse events and maintaining adherence. Payers and clinicians look for:

  • Manageable rash and ocular events
  • Cardiac monitoring adherence and predictable management of cardiomyopathy risk
  • Dose modification protocols that reduce discontinuations

Formulary and reimbursement

Since trametinib is a chronic on-treatment therapy in oncology settings, reimbursement positioning is strongly affected by:

  • Evidence strength in the assigned line of therapy
  • Demonstrated benefit in the labeled regimen
  • Cost-effectiveness assessments based on PFS/OS gains

Key Takeaways

  • Mekinist (trametinib) is a MEK inhibitor with commercial exposure concentrated in advanced melanoma combinations, especially in BRAF V600-mutant disease.
  • Clinical progress is most likely incremental through combination optimization, sequencing, and label-sustaining studies rather than a single replacement product.
  • Market growth is likely modest over the next 3–5 years, driven by ongoing regimen uptake, persistence, and any label expansions that change guideline placement.
  • Forecast upside depends on trial readouts that shift first-line or broaden indication scope, while downside risk comes from faster payer and guideline migration to alternative standards.

FAQs

1) What is Mekinist’s mechanism of action?

Mekinist is trametinib, a MEK inhibitor that blocks MEK signaling in the MAPK pathway.

2) Where is Mekinist primarily used today?

Primarily in advanced melanoma settings where MEK inhibition is used alone or with BRAF-targeted therapy.

3) What drives Mekinist market performance?

Adoption of guideline-recommended regimens, especially combination use, plus persistence, discontinuation rates, and pricing.

4) What trial outcomes most affect future growth?

PFS, OS, ORR, and durability in combination or label expansion studies, alongside safety in real-world-like populations.

5) What is the most credible direction for near-term growth?

Incremental growth via combination adoption and potential label expansions rather than a step-change based on monotherapy resurgence.


References

[1] FDA. Mekinist (trametinib) Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/
[2] EMA. Mekinist (trametinib) Product Information. European Medicines Agency. https://www.ema.europa.eu/
[3] ClinicalTrials.gov. Trametinib (Mekinist) clinical trials. https://clinicaltrials.gov/
[4] Novartis. Mekinist (trametinib) pipeline and publications. https://www.novartis.com/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.